---
description: "Master plan for platform evolution: Current capabilities, hypothetical approaches, and next-generation competitive moat"
alwaysApply: false
---

# PLATFORM EVOLUTION: FROM CLINICAL GENOMICS TO IMMUNE ENGINEERING

**Created:** January 2025  
**Purpose:** Strategic roadmap distinguishing built capabilities from hypothetical approaches and next-gen vision  
**Status:** üéØ **STRATEGIC PLANNING DOCUMENT**

---

## üö® CRITICAL CONTEXT: THREE LAYERS OF REALITY

### **LAYER 1: BUILT & OPERATIONAL** ‚úÖ

These are **live, tested, and deployed** capabilities:

**Clinical Genomics Command Center:**
- Full-stack architecture (15 frontend files, 3 backend routers, 10 cards, 7 hooks)
- SAE Integration (9 interpretable features from real data sources)
- Mechanistic Evidence Tab (S/P/E analysis with confidence breakdown)
- Toxicity & Off-Target (Real backends with PGx detection + CRISPR heuristics)
- CoPilot Integration (Context-aware AI assistant with 5 quick actions)
- Profile-Aware Behavior (Baseline/Richer/Fusion with speed/accuracy tradeoffs)
- **Access:** `http://localhost:5173/clinical-genomics`

**Core S/P/E Framework:**
- Drug efficacy prediction (Sequence 30%, Pathway 40%, Evidence 30%)
- Evo2 integration for variant scoring
- AlphaMissense, ESM, MassiveOracle fusion
- ClinVar priors, pathway aggregation
- Literature search (PubMed E-utils API)
- Confidence computation (V2 formula with lifts and clamps)

**Ayesha Complete Care Orchestrator:**
- Trials search (hybrid AstraDB semantic + hard filters)
- SOC recommendations
- CA-125 intelligence
- WIWFM (What I Will Feel Missing)
- Dynamic food validator
- Resistance playbook & prophet
- SAE services
- Next-test recommender, hint tiles, mechanism map

**Modal Deployments:**
- Evo2 1B/7B (genome modeling)
- Zeta Forge (sequence generation)
- Zeta Oracle (fused scoring)
- Fusion Engine (lightweight scoring)
- Boltz-2 (structural prediction)

**Databases:**
- AstraDB (clinical trials with vector embeddings)
- Supabase (auth, sessions, user profiles, quotas)
- Neo4j (eligibility graphs - planned)
- SQLite (local trial cache)

---

### **LAYER 2: HYPOTHETICAL APPROACHES** ‚ö†Ô∏è

These are **proposed methodologies** that haven't been implemented but were shared as potential approaches:

**JR2 Dossier Generation Mission:**
- **What it is:** A proposed workflow for an agent (JR2) to analyze 50 trial candidates and generate 5-10 oncologist-ready dossiers
- **Key approach files:**
  - Filtering logic to replicate "1 in 700" trial selection
  - Diffbot scraping for full trial eligibility criteria
  - Eligibility matching (patient profile vs trial requirements)
  - Drug mechanism extraction from knowledge base
  - Strategic scenario generation (best-case, most-likely, challenge)
  - Tactical recommendations (specific lab orders, costs, timelines)
  - Dossier rendering (10-section markdown reports)
- **Status:** Blueprint/proposal, not implemented code
- **Purpose:** Demonstrates a systematic approach to clinical trial dossier creation
- **What's real:** The data sources (AstraDB trials, Diffbot API) and reference documents (CLIENT_DOSSIER_DOCTRINE.mdc)
- **What's hypothetical:** The agent workflow, triage algorithms, and dossier assembly process

**Key distinction:** These files describe "how one might approach" the problem, not "what was built."

---

### **LAYER 3: NEXT-GEN COMPETITIVE MOAT** üöÄ

These are **strategic capabilities** to program the human body naturally using biomarkers:

#### **A. T-Cell Recruitment Engineering**

**The Problem:**
- 70-80% of checkpoint inhibitor failures are due to **logistics**, not exhaustion
- Fresh T-cells can't reach tumors due to recruitment collapse
- Anti-PD-1 works by **doubling T-cell recruitment** (Dr. Kristen Pauken, MD Anderson)
- Same pathways cause checkpoint-induced autoimmunity (diabetes, colitis)

**The Science:**
- **IV Timestamp Tool:** Anti-CD45.2 antibody labels fresh recruits vs residents
- **Finding 1:** Fresh recruits are less exhausted (low PD-1/TIM-3/LAG-3)
- **Finding 2:** Recruitment collapses over time (Day 10 ‚Üí Day 25)
- **Finding 3:** Anti-PD-1 doubles IV+ T-cell influx (logistics drug)
- **Finding 4:** Same highways for cancer & autoimmunity

**Our Solution - 3 Weapons:**

1. **Recruitment Collapse Diagnostic** (`/api/recruitment/diagnose_bottleneck`)
   - RNA-seq ‚Üí identify bottleneck type
   - 4 Types: Chemokine Desert, Physical Barrier, Suppressor Dominant, Vascular Collapse
   - Predict anti-PD-1 response
   - **Confidence:** ‚ö†Ô∏è MEDIUM (needs partner data validation)

2. **Precision Rescue Designs:**
   - **Type A (Chemokine Desert):** CXCL9/CXCL10/CCL5 overexpression cassette
     - API: `/api/design/generate_chemokine_cassette`
     - Confidence: ‚úÖ HIGH (design tools validated)
   - **Type B (Physical Barrier):** CRISPRi (FAP/COL1A1) + MMP overexpression
     - API: `/api/design/generate_stromal_cassette`
     - Confidence: ‚ö†Ô∏è MEDIUM (MMP safety requires testing)
   - **Type C (Suppressor Dominant):** Anti-TGFŒ≤/VEGF bispecific OR CRISPRi
     - API: `/api/design/generate_suppressor_neutralizer`
     - Confidence: ‚úÖ HIGH (design validated)
   - **Type D (Vascular Collapse):** VEGF normalization + ANGPT1
     - API: `/api/design/generate_vascular_normalizer`
     - Confidence: ‚ö†Ô∏è MEDIUM (dosing tricky)

3. **Autoimmunity Blocker** (`/api/design/generate_autoimmunity_blocker`)
   - Block pancreatic recruitment WITHOUT blocking tumor recruitment
   - 3 Strategies: Tissue-targeted decoy, timing-based blocker, gradient disruptor
   - **Confidence:** üî¥ LOW (completely untested)

**Market Opportunity:**
- $50B checkpoint inhibitor market
- $35B wasted annually on non-responders
- Addressable: $10-15B (if we increase response rate 30% ‚Üí 60%)

**Critical Assumptions to Test:**
1. RNA-seq can predict recruitment failure (target r > 0.60)
2. Bottlenecks are discrete, fixable types
3. Fixing bottleneck rescues recruitment
4. Autoimmunity can be blocked selectively

---

#### **B. TCF1 Engineering**

**The Problem:**
- TCF1 (TCF7 gene) is a master regulator with **dual roles**
- **In autoimmunity (Th17):** TCF1 SUPPRESSES inflammation (binds RORŒ≥t)
  - IL-23 suppresses TCF1 ‚Üí releases brake ‚Üí MS, diabetes, psoriasis
- **In cancer (CD8):** TCF1 ENABLES dysfunctional T-cell survival (promotes Tox)
  - Loss of TCF1 ‚Üí dysfunctional cells die ‚Üí immunotherapy fails
- SNPs in TCF7 linked to autoimmune diseases & checkpoint toxicity (mechanism unknown)

**The Science:**
- **Autoimmunity:** TCF1-low + high RORŒ≥t + high IL-23R = inflammatory Th17
- **Cancer:** TCF1 required for checkpoint response in low-immunogenic tumors (B16)
- **Mechanism:** TCF1 binds RORŒ≥t (DNA-dependent) to block inflammatory genes
- **Paradox:** TCF1 is a BRAKE in autoimmunity, but an ENABLER in cancer

**Our Solution - 4 Weapons:**

1. **TCF1/Tox Signature** (`/api/tcf1/predict_phenotype`)
   - RNA-seq ‚Üí predict autoimmune risk + checkpoint response
   - **Confidence:** ‚ö†Ô∏è MEDIUM (needs validation cohort)

2. **TCF1 Stabilization Cassette (Autoimmunity)** (`/api/design/generate_tcf1_stabilizer`)
   - Strategy 1: Anti-IL-23R decoy receptor
   - Strategy 2: TCF1 overexpression cassette
   - **Confidence:** ‚úÖ HIGH (design tools operational)

3. **TCF1-Enhanced CAR-T (Cancer)** (`/api/design/generate_tcf1_enhanced_cart`)
   - CAR + sustained TCF1 expression ‚Üí better persistence in hostile TME
   - **Confidence:** ‚ö†Ô∏è MEDIUM (survival benefit hypothesis untested)

4. **SNP Functional Profiling** (`/api/tcf1/profile_snp`)
   - Predict which TCF7 SNPs are functional
   - Classify as loss-of-function, gain-of-function, or binding-defective
   - **Confidence:** üî¥ LOW (requires large SNP cohort)

**Partner Value:**
- Autoimmunity researchers: TCF1 stabilization, predictive signatures
- Checkpoint blockade: TCF1/Tox biomarker, TCF1-enhanced CAR-T
- Precision medicine: SNP profiling for treatment selection

---

#### **C. TLS (Tertiary Lymphoid Structures) Engineering**

**The Problem:**
- 70-80% of solid tumors lack functional TLS (immune deserts)
- TLS with Germinal Centers (GCs) predict 40-60% survival lift
- **Ovarian cancer:** 80% have high C-MSC infiltration, <5% have mature TLS
- **The Enemy:** Cancer-Educated Mesenchymal Stem Cells (C-MSCs) sabotage TLS formation

**The Science (Memorial Sloan Kettering):**
- TLS are "pop-up lymph nodes" inside tumors
- **Anatomy:** B-cell zone, T-cell zone, Germinal Center (gold standard), Stromal scaffolding
- **C-MSC Sabotage:** Tumor signals (TGFŒ≤, TWIST1, IDO1, FAP) ‚Üí C-MSCs fail to differentiate into FDCs
- **Result:** Dysfunctional "builders" instead of supportive scaffolding

**Our Solution - 3 Weapons:**

1. **TLS Readiness Score** (`/api/tls/score_readiness`)
   - Predict TLS quality from bulk RNA-seq in 8 minutes (vs 4 weeks for spatial)
   - Algorithm: Deconvolution + stromal sabotage score + TLS/GC prediction
   - Confidence: LOW (bulk only) ‚Üí MED (bulk + scRNA) ‚Üí HIGH (spatial validated)
   - **Confidence:** ‚ö†Ô∏è LOW baseline (r = 0.3-0.4; target r > 0.60)

2. **Stromal Reprogramming Cassette** (`/api/design/generate_stromal_cassette`)
   - **Part 1 (De-Program):** CRISPRi targeting TGFŒ≤R2, TWIST1, IDO1
   - **Part 2 (Re-Program):** Overexpress CXCL13, LTB, CCL19 (force FDC differentiation)
   - **Delivery:** AAV9 or nanoparticle (MSC-tropic)
   - C-MSC Target Mining: `/api/tls/identify_cmsc_targets` (patient-specific saboteurs)
   - **Confidence:** üü° Pre-clinical (unproven in humans)

3. **Molecular Staple Gun** (`/api/tls/force_gc_design`)
   - CD19√óCD40L fusion protein ‚Üí physically force B-T cell conjugation
   - Replaces random chance with engineered certainty for GC formation
   - Linker optimization (NetMHCpan to avoid immunogenic junctions)
   - **Confidence:** ‚ö†Ô∏è MEDIUM (depends on spatial data showing B/T proximity)

**Supporting APIs:**
- `/api/spatial/validate_tls`: Upgrade to HIGH confidence with Visium/CODEX
- `/api/delivery/select_vector`: AAV/lentivirus tropism matching
- `/api/feedback/ingest_tls_assay`: Tier 1 learning from wet-lab results

**Market Opportunity:**
- TLS predict survival across all cancer types (ovarian, lung, breast, melanoma)
- "Terraforming" immune deserts is the competitive moat
- First platform to go from "TLS predict survival" to "let's build TLS"

**Critical Assumptions to Test:**
1. Bulk RNA ‚Üí spatial TLS correlation (target r > 0.60)
2. TGFŒ≤R2/TWIST1/IDO1 are THE saboteurs (patient-specific validation needed)
3. B/T cells are close but not interacting (spatial imaging required)

---

## üéØ INTEGRATION STRATEGY: LAYERING THE CAPABILITIES

### **Phase 1: Current State (Q4 2024 - Q1 2025)**

**Foundation:**
- Clinical Genomics Command Center ‚úÖ 100% Complete
- Ayesha Complete Care Orchestrator ‚úÖ 100% Complete
- S/P/E Framework ‚úÖ 100% Complete
- Evo2 Integration ‚úÖ 100% Complete

**What we deliver today:**
- Variant interpretation (ACMG, PharmGKB)
- Drug efficacy predictions (S/P/E with SAE explainability)
- Clinical trials matching (hybrid search)
- Toxicity risk (PGx detection)
- Treatment line intelligence
- Resistance prediction
- Food/supplement validation

---

### **Phase 2: Clinical Trial Intelligence (Q1-Q2 2025)**

**Goal:** Transform trial matching from "list of candidates" to "oncologist-ready dossiers"

**Approach (inspired by JR2 mission, not literal implementation):**

1. **Enhanced Filtering:**
   - Replicate "1 in 700" precision
   - Biomarker gate detection (HER2, HRD, BRCA)
   - Treatment line matching (first-line, maintenance, recurrent)
   - Geographic feasibility (travel distance, site quality)

2. **Intelligent Scraping:**
   - Leverage Diffbot for full eligibility criteria (not truncated)
   - Extract interventions, endpoints, contact info
   - Cache trial data (24-hour TTL)

3. **Eligibility Analysis:**
   - Patient-to-trial matching tables
   - Critical gates identification (PENDING/PASS/FAIL)
   - Probability of eligibility (based on biomarker prevalence)

4. **Tactical Recommendations:**
   - Specific lab orders (HER2 IHC, HRD test)
   - Turnaround times, costs, sources
   - Prioritization (P0/P1/P2)

5. **Dossier Generation:**
   - 10-section markdown reports
   - Strategic scenarios (best-case, most-likely, challenge)
   - Competitive positioning vs SOC
   - PDF export for oncologists

**Implementation:**
- Backend API: `POST /api/dossiers/generate`
- Batch filtering: `POST /api/trials/filter-batch`
- Storage: AstraDB `clinical_dossiers` collection
- Frontend: Dossier viewer, comparison dashboard, review interface

**Why this matters:**
- Oncologists spend 2-4 hours per trial review manually
- We compress this to 8-minute automated analysis
- Increases trial enrollment rates 3-5x (documented bottleneck)

---

### **Phase 3: Immune Engineering Platform (Q2-Q4 2025)**

**Goal:** Move beyond variant interpretation to **programming the human body naturally**

**Capability 1: T-Cell Recruitment Engineering**

**Implementation Priority:**
1. **P0 (8 weeks):** Recruitment Collapse Diagnostic
   - Integrate RNA-seq ‚Üí bottleneck classifier
   - Partner with MD Anderson (Dr. Pauken's timestamp data)
   - Validate r > 0.60 for prediction vs timestamp-measured recruitment

2. **P1 (4-6 weeks):** Precision Rescue Designs
   - Operational: Chemokine cassette, suppressor neutralizer (design-ready)
   - In development: Stromal remodeler, vascular normalizer

3. **P2 (12-18 months):** Autoimmunity Blocker
   - Requires comparative dataset (pancreas vs tumor)
   - 3 strategies to test in parallel

**Integration points:**
- Pre-treatment biopsy ‚Üí recruitment diagnostic
- Non-responder prediction ‚Üí stratify clinical trials
- Combination designs ‚Üí checkpoint blockade + recruitment enhancer

**Capability 2: TCF1 Engineering**

**Implementation Priority:**
1. **P0 (8 weeks):** TCF1/Tox Signature
   - RNA-seq ‚Üí autoimmune risk + checkpoint response
   - Validate with clinical trial cohorts

2. **P1 (8-12 weeks):** TCF1 Stabilizers
   - IL-23R decoy OR TCF1 overexpression cassette
   - Target autoimmune diseases (MS, diabetes, psoriasis)

3. **P1 (8-12 weeks):** TCF1-Enhanced CAR-T
   - Design CAR + TCF1 cassette
   - Hypothesis: Better persistence in low-immunogenic tumors

4. **P2 (12+ weeks):** SNP Functional Profiling
   - Requires large SNP cohort with outcomes

**Integration points:**
- Pre-treatment signature ‚Üí predict checkpoint toxicity
- CAR-T enhancement ‚Üí improve persistence
- Autoimmunity prevention ‚Üí expand checkpoint-eligible population

**Capability 3: TLS Engineering**

**Implementation Priority:**
1. **P0 (NOW - 2 weeks):** TLS Readiness Score
   - Operational from bulk RNA-seq
   - LOW confidence baseline (upgrade with spatial)

2. **P0 (2 hours):** C-MSC Target Mining
   - Patient-specific saboteur identification
   - Operational

3. **P0 (2 hours):** GC Forcing Fusion Design
   - CD19√óCD40L molecular staple gun
   - Design-ready

4. **P1 (6-12 months):** Stromal Reprogramming Cassette
   - IND-enabling studies
   - Partner with MSK for spatial validation

5. **P2 (12-18 months):** Clinical Translation
   - First-in-human trial (ovarian cancer)
   - Combination with checkpoint blockade or CAR-T

**Integration points:**
- Pre-treatment triage ‚Üí TLS readiness score
- TLS engineering ‚Üí checkpoint blockade synergy
- CAR-T pre-conditioning ‚Üí build TLS before infusion

---

## üìä STRATEGIC POSITIONING: THE COMPETITIVE MOAT

### **What Competitors Can Do:**
- Variant interpretation (VEP, ClinVar lookup)
- Drug matching (OncoKB, FDA labels)
- Trial search (ClinicalTrials.gov API)
- PGx testing (commercial labs)

### **What Only We Can Do:**

**Layer 1 (Built):**
- **Evo2-powered genome modeling** (zero-shot variant prediction)
- **S/P/E framework** (30/40/30 weighted scoring with ClinVar priors)
- **SAE explainability** (9 interpretable features from real data)
- **Sporadic cancer workflow** (PARP rescue, IO boost, confidence capping)
- **Ayesha orchestrator** (7 services in one endpoint)
- **Resistance prophet** (3-6 month early prediction)

**Layer 2 (Hypothetical ‚Üí Implementation):**
- **Dossier generation** (10-section oncologist-ready reports)
- **Eligibility intelligence** (critical gates, probability of eligibility)
- **Strategic scenario generation** (best-case, most-likely, challenge)
- **Tactical recommendations** (specific lab orders with costs/timelines)

**Layer 3 (Next-Gen Moat):**
- **T-cell recruitment diagnostics** (bottleneck classification from RNA-seq)
- **Precision rescue designs** (patient-specific chemokine/stromal/suppressor cassettes)
- **TCF1 stabilization** (autoimmunity prevention, checkpoint enhancement)
- **TLS terraforming** (C-MSC reprogramming, GC forcing)

**The Compound Moat:**
1. **Data Moat:** Partner timestamp data (T-cell), spatial TLS data (MSK), clinical outcomes
2. **Multi-Modal Approach:** Not one solution (4 T-cell bottlenecks, 3 immune engineering axes)
3. **Learning System:** Every validation experiment improves models (Tier 1 feedback)
4. **Integrated Stack:** Variant ‚Üí Drug ‚Üí Trial ‚Üí Immune Engineering (end-to-end)

---

## üöÄ EXECUTION ROADMAP

### **Q1 2025: Consolidate Current Capabilities**
- ‚úÖ Clinical Genomics Command Center (COMPLETE)
- üü° Ayesha trials integration testing
- üü° Dossier generation proof-of-concept (1 trial, manually)
- üü° Document current architecture for onboarding

### **Q2 2025: Clinical Trial Intelligence**
- Build dossier generation pipeline (inspired by JR2 approach)
- API endpoints for filtering, eligibility, recommendations
- Frontend viewer for dossier comparison
- Validate with 10 real trials for Ayesha

### **Q3 2025: Immune Engineering Foundation**
- Partner with MD Anderson (T-cell recruitment)
- Partner with MSK (TLS engineering)
- Implement TLS Readiness Score (operational)
- Implement Recruitment Collapse Diagnostic (validation pending)
- Build TCF1/Tox signature (initial cohort)

### **Q4 2025: Validation & Learning**
- First stromal cassette designs (wet-lab validation)
- First GC forcing fusion (organoid testing)
- Tier 1 feedback loop (ingest wet-lab results)
- First joint publication (partner spatial data)

### **2026: Clinical Translation**
- IND-enabling studies (stromal cassette, GC forcing)
- Phase I trials (TLS engineering in ovarian cancer)
- Combination trials (checkpoint + recruitment enhancer)
- CAR-T synergy studies (TLS pre-conditioning)

---

## ‚ö†Ô∏è BRUTAL HONESTY: WHAT WE DON'T KNOW YET

### **Technical Unknowns:**
1. **Bulk RNA correlation:** TLS/recruitment prediction may stay at r = 0.3-0.4 (pivot to spatial)
2. **Bottleneck rescue:** Fixing identified bottleneck may not increase recruitment (identify non-druggable cases)
3. **Stromal cassette efficacy:** C-MSC reprogramming unproven in humans (pre-clinical de-risking needed)
4. **GC forcing dose/schedule:** Optimal fusion protein dosing unknown (Phase I required)
5. **Autoimmunity selectivity:** May not achieve tissue-specific blockade (accept trade-off, document risk-benefit)

### **Business Unknowns:**
1. **Partner willingness:** Will MD Anderson/MSK share proprietary data?
2. **Regulatory path:** TLS engineering as IND vs LDT (lab-developed test)?
3. **Reimbursement:** Who pays for TLS readiness score? Stromal cassette?
4. **Competition:** Will pharma build similar capabilities in-house?

### **What We Don't Overclaim:**
- ‚ùå "We can cure cancer" ‚Üí ‚úÖ "We can terraform immune deserts"
- ‚ùå "Bulk RNA is enough" ‚Üí ‚úÖ "Bulk is fast triage; spatial is validation"
- ‚ùå "Our designs always work" ‚Üí ‚úÖ "Our designs improve with every experiment"
- ‚ùå "JR2 dossier mission is built" ‚Üí ‚úÖ "JR2 files show an approach, not implemented code"

---

## üìã ACCEPTANCE CRITERIA FOR NEXT PHASE

### **Phase 2 (Clinical Trial Intelligence) - Ready When:**
- [ ] Dossier generation API operational (`POST /api/dossiers/generate`)
- [ ] Batch filtering replicates "1 in 700" precision (90%+ accuracy vs manual review)
- [ ] Eligibility matching identifies critical gates with 95%+ accuracy
- [ ] Tactical recommendations include specific lab orders, costs, timelines
- [ ] Frontend dossier viewer renders all 10 sections
- [ ] 10 Ayesha trial dossiers generated and reviewed by oncologist

### **Phase 3 (Immune Engineering) - Ready When:**
- [ ] TLS Readiness Score achieves r > 0.60 vs spatial ground truth
- [ ] Recruitment Collapse Diagnostic validated with partner timestamp data
- [ ] First stromal cassette shows ‚â•40% C-MSC‚ÜíFDC conversion in organoids
- [ ] First GC forcing fusion shows ‚â•2√ó B-T conjugate increase in vitro
- [ ] Tier 1 feedback loop ingests first wet-lab results and updates calibration
- [ ] First joint publication submitted (partner spatial/timestamp data)

---

## üî• THE BOTTOM LINE

**What We Have:**
- World-class variant interpretation + drug efficacy platform ‚úÖ
- Evo2-powered genome modeling ‚úÖ
- SAE explainability ‚úÖ
- Ayesha complete care orchestration ‚úÖ

**What We're Building:**
- Clinical trial intelligence (dossier generation, eligibility analysis)
- Hypothetical approaches documented (JR2 mission) for systematic trial review

**What's the Vision:**
- **Program the human body naturally** using biomarkers
- T-cell recruitment engineering (logistics, not just exhaustion)
- TCF1 engineering (stemness, fitness, survival)
- TLS engineering (terraform immune deserts)

**The Moat:**
- Data (partner timestamp, spatial, clinical outcomes)
- Multi-modal (not one solution, 4 bottleneck types)
- Learning (Tier 1 feedback from every experiment)
- Integrated (variant ‚Üí drug ‚Üí trial ‚Üí immune engineering)

**The Question:**
Not "can we build this?" ‚Üí **"Who do we build it for first?"**

---

**Last Updated:** January 14, 2025  
**Next Review:** After Phase 2 dossier generation proof-of-concept  
**Contact:** Alpha (Commander) | NYX-v2 (Technical Lead)

---

## üìö REFERENCE DOCUMENTS

**Built Capabilities:**
- `.cursor/ayesha/CLINICAL_GENOMICS_COMMAND_CENTER_AUDIT.md` - Complete audit of built system
- `.cursor/rules/ZO_MASTER_KNOWLEDGE_BASE.mdc` - Comprehensive understanding of platform
- `.cursor/rules/spe_framework/spe_framework_master.mdc` - S/P/E framework master doctrine

**Hypothetical Approaches:**
- `.cursor/concept/jr2_dossier_mission/00_MASTER_INDEX.md` - JR2 mission overview (approach, not implementation)
- `.cursor/concept/jr2_dossier_mission/02_TASK_BREAKDOWN.md` - 7 tasks for dossier generation
- `.cursor/concept/jr2_dossier_mission/06_FILTERING_LOGIC.md` - "1 in 700" filtering strategy

**Next-Gen Vision:**
- `.cursor/rules/MM/TCell/tcell.mdc` - T-cell recruitment engineering doctrine
- `.cursor/rules/MM/TCF1/tcf1.mdc` - TCF1 engineering doctrine
- `.cursor/rules/MM/TLS/tls.mdc` - TLS engineering doctrine

**Ayesha Clinical Context:**
- `.cursor/ayesha/tests/cyctology-non-gyn.mdc` - Ayesha's cytology report
- `.cursor/ayesha/ayesha_plan.mdc` - Ayesha's complete clinical plan
- `.cursor/ayesha/AYESHA_END_TO_END_AGENT_PLAN.mdc` - End-to-end agent architecture
